Dvago Logo
    location icon

    Dvago Logo

    Delivers in

      location icon


      Aromasin Tablets 25Mg

      Rs. 7,398.75

      Rs. 7,788.22




      Requires Prescription (YES/NO)




      Used For


      How it works

      Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation, an effect also known as suicide inhibition. Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.




      Side Effects

      Hot flushes , increased sweating , trouble sleeping , feeling tired , joint pain, headache .

      Drug Interactions

      Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's wort) may significantly decrease exposure to exemestane.


      It is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy . Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy .

      When not to Use

      Patients with a known hypersensitivity to the drug or to any of the excipients .



      It should not be administered to premenopausal women. It should not be coadministered with estrogen-containing agents as these could interfere with its pharmacologic action.


      Warning 1

      Tell your doctor if you have a history or are suffering from any condition which affects the strength of your bones. Your doctor may want to measure your bone density before and during the treatment of exemestane. This is because medicines of this class lower the levels of female hormones and this may lead to a loss of the mineral content of bones, which might decrease their strength.

      Warning 2

      Routine checking of your vitamin D level will also be made before treatment, as your level may be very low in the early stages of breast cancer. You will be given vitamin D supplement if your levels are below normal.

      Warning 3

      Patients with advanced disease should have their bone mineral density assessed on a case by case basis. Although adequate data to show the effects of therapy in the treatment of the bone mineral density loss caused by exemestane are not available, patients treated with exemestane should be carefully monitored and treatment for, or prophylaxis of, osteoporosis should be initiated in at risk patients.


      Pregnancy category

      Always consult your physician before using any medicine.

      Storage (YES/NO)

      Store this medicine at room temperature, away from direct light and heat.

      Related Products